COVID-19

Kalorama Information’s latest report, The Market and Potential for Molecular Point of Care (mPOC), 2021, provides comprehensive market sizing, forecasting, trend mapping, and competitive analysis for point of care (POC) tests using PCR or other molecular technologies. Designed for near-patient settings, these tests offer fast turnaround times. Major in vitro diagnostic (IVD) companies such as…

Explore the comprehensive analysis of the POC testing market, its growth prospects, and the key players driving innovation in this essential segment of the healthcare industry in Kalorama Information’s report, The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 8th Edition.

By the middle of the decade, the global point-of-care (POC) testing market is expected to…

Sepsis poses one of the greatest challenges in healthcare today, with approximately 1.7 million cases and 270,000 deaths annually in the United States alone. The condition is the most expensive to treat in US hospitals, highlighting the urgent need for effective diagnosis and treatment solutions. Kalorama Information’s report, Sepsis Diagnostics Products and Market Trends, provides…

Urgent care centers (UCCs) are a vital and growing segment of the U.S. healthcare system, with around 10,000 locations nationwide. They offer walk-in care, a broad range of services, extended hours, and minimal wait times. Kalorama Information’s report, The U.S. Market for Urgent Care Centers (Including COVID-19, POC Tests, Vaccines and Other Sales), 2^nd Edition,…

We’ve Spoken To Your Customers

Understanding the overall customer experience, from pre-purchase experience, to product experience, to post-purchase experience, is more important now than ever before. Customer experience offers an opportunity for suppliers to differentiate themselves from other suppliers in a crowded life science marketplace on something more than product performance and price. An excellent…

Companion diagnostics are revolutionizing pharmaceutical development and treatment, particularly in oncology. By identifying patients with specific biomarkers or disease-specific therapeutic targets, companion diagnostics significantly improve clinical success rates and patient outcomes. They also reduce costs by pinpointing the patient population most likely to benefit from a therapy and excluding those for whom the therapy would…